SVB Financial Group (SIVB) News
Filter SIVB News Items
SIVB News Results
|Loading, please wait...|
SIVB News Highlights
- For SIVB, its 30 day story count is now at 17.
- Over the past 27 days, the trend for SIVB's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- III, WD and ACHV are the most mentioned tickers in articles about SIVB.
Latest SIVB News From Around the Web
Below are the latest news stories about Svb Financial Group that investors may wish to consider to help them evaluate SIVB as an investment opportunity.
SVB Financial Group (SVB), financial partner to the innovation economy, today announced that Roger Dunbar will retire from his role as the Chairman of the Board on April 21, 2022, after a decade in the position. He will remain in his current role through the 2022 annual shareholder meeting. Kay Matthews, current SVB board member, will become the board Chair at that time. Board member John Clendening will step off SVB's board at the end of this term.
Bay Area investment bank SVB Securities sees another banner year for acquisitions amid market volatility
“Having periods in the market where there’s dislocation and volatility, that’s when clients need the most attention,” said SVB Securities CEO Jeff Leerink.
In a report released today, David Chiaverini from Wedbush reiterated a Buy rating on Svb Financial Group (SIVB – Research Report), with a price target of $860.00. The company's shares closed last Tuesday at $645.23. According to TipRanks.com, Chiaverini is a 5-star analyst with an average return of 19.0% and a 65.8% success rate. Chiaverini covers the Financial sector, focusing on stocks such as Pacific Premier Bancorp, Valley National Bancorp, and Cathay General Bancorp. Currently, the analyst consensus on Svb Financial Group is a Moderate Buy with an average price target of $813.86, a 27.0% upside from current levels.
In this article, we discuss 10 stocks to buy amid rising interest rates. If you want to skip our detailed analysis of these stocks, go directly to 5 Stocks to Buy Amid Rising Interest Rates. In late January, Jerome Powell, the US central bank chief, told reporters at a news conference that the Federal Reserve […]
Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley Bank
EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on February 4, 2022, it entered into a debt facility of up to $80 million with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules") and Silicon Valley Bank (NASDAQ: SIVB) ("SVB"). "This debt financing will provide Lucira l
More Americans might raise cash by selling stakes in their home equity as rising interest rates make borrowing against their home equity more expensive.
Investment company Mine & Arao Wealth Creation & Management, LLC. (Current Portfolio) buys PayPal Holdings Inc, Clorox Co, iShares China Large-Cap ETF, Vanguard Real Estate Index Fund ETF, Starbucks Corp, sells AT&T Inc, Verizon Communications Inc, iShares Core MSCI Emerging Markets ETF, Rocket Inc, Wynn Resorts during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mine & Arao Wealth Creation & Management, LLC..
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th, when the S&P 500 Index was trading around the […]
Since launching Peacock in the summer of 2020, Comcast's (NASDAQ: CMCSA) management hasn't provided a lot of details on the business. The biggest news from management was its plan to double its content spending for Peacock in 2022 from $1.5 billion to $3 billion. Here's what's giving management the confidence to double down on Peacock, and how that will impact investors.
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Since Our Last Update Since our last update , Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced several milestones. In January, Achieve’s pivotal, Phase III ORCA-2 1 trial had its last subject, last follow up, and the confirmatory Phase III ORCA-3 trial was initiated. In addition, Achieve hosted a key opinion leader panel